Please ensure Javascript is enabled for purposes of website accessibility

Moderna's New COVID-19 Vaccine Ready for Human Trials; Stock Up 15%

By Mark Prvulovic - Feb 24, 2020 at 8:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The first batch of the new mRNA vaccine has been shipped for early clinical testing.

Moderna (MRNA 8.73%) announced on Monday afternoon that the company's experimental mRNA COVID-19 vaccine, known as mRNA-1273, is ready for human testing. The initial batch of the vaccine has already been shipped to U.S. government researchers from the National Institute of Allergy and Infectious Diseases (NIAID).

The biotech company expects that the first clinical trials will begin near late April, with around 25 healthy volunteers participating in these tests. Initial clinical results could be available sometime in July or August.

Multiple vials of a coronavirus vaccine on a table.

Image source: Getty Images.

It's a remarkably fast development cycle for Moderna to be able to develop an initial vaccine just weeks after identifying the COVID-19 genetic sequence.

"Going into a phase one trial within three months of getting the sequence is unquestionably the world indoor record," said NIAID Director Anthony Fauci in an interview. "Nothing has ever gone that fast," 

Further details

Moderna's mRNA technology is quite promising, with mRNA vaccines hypothetically being faster and more effective than their DNA-based counterparts. This is because DNA-based vaccines need to interact with the nucleus of the cell, whereas mRNA (or messenger RNA) is found all across the cell and is much more accessible. However, given that mRNA vaccines have never been tested before on humans, it's still uncertain how well Moderna's new coronavirus vaccine will perform.

While Moderna's vaccine is a newly developed treatment, other companies have found success in using drugs designed for other, similar conditions. Gilead Sciences' remdesivir, an Ebola drug, has been effective in helping reduce COVID-19 symptoms, with the World Health Organization (WHO) touting its potential in a statement early today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$147.66 (8.73%) $11.86
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$64.80 (0.51%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.